trending Market Intelligence /marketintelligence/en/news-insights/trending/vS43CF-mtUz9Y_PuYno-wA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Gilead sees YOY decline in Q3 profit despite uptick in sales

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Gilead sees YOY decline in Q3 profit despite uptick in sales

Gilead Sciences Inc.'s earnings for the third quarter of 2019 fell versus the same period last year despite a year-over-year bump in product sales.

Non-GAAP net income for the quarter decreased to $2.22 billion, or $1.75 per share, from $2.40 billion, or $1.84 per share, in the year-ago period. The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was $1.73.

On a GAAP basis, net loss attributable to Gilead was $1.17 billion, or 92 cents per share, compared to net income of $2.10 billion, or $1.60 per share, a year ago.

The net loss includes $3.92 billion, or $2.40 per share, in up-front collaboration and licensing expenses related to Gilead’s global research and development collaboration agreement with Galapagos NV.

Foster City, Calif.-based Gilead reported total revenue of $5.60 billion for the third quarter, almost flat compared to the year-ago period. Gilead's non-GAAP research and development expenses during the quarter increased year over year to $954 from $844 million.

The biotechnology company said its quarterly product sales increased to $5.52 billion from $5.46 billion in the same period a year ago.

HIV product sales were $4.20 billion for the third quarter of 2019, compared to $3.72 billion for the third quarter of 2018. The increase in sales is mainly attributed to a rise in uptake of Biktarvy, which saw total sales of $1.26 billion for the quarter.

The sales of chronic hepatitis C products — which comprise Epclusa, Harvoni, Vosevi and Sovaldi — this quarter were down 25.3% to $674 million from $902 million in the third quarter of 2018. The decline was primarily due to competitive dynamics, Gilead noted in its Oct. 24 earnings release.

Gilead increased its forecast for product sales during the full year to be in the range of $21.80 billion to $22.10 billion, compared to earlier expectations of $21.60 billion to $22.10 billion. The company also increased its expectations for research and development expenses to be in the range of $3.70 billion to $3.80 billion.

Gilead expects the EPS impact of acquisitions, up-front collaboration, stock-based compensation and other expenses for 2019 to be in the range of $3.90 to $4.00.